<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pulmonary complications of inflammatory bowel disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pulmonary complications of inflammatory bowel disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pulmonary complications of inflammatory bowel disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven E Weinberger, MD, MACP, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark A Peppercorn, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sunanda V Kane, MD, MSPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory bowel disease (IBD) is associated with a variety of conditions outside of the gastrointestinal tract, termed extraintestinal manifestations of IBD  (
         <a class="graphic graphic_table graphicRef81867" href="/z/d/graphic/81867.html" rel="external">
          table 1
         </a>
         ). Since the original report in 1976 of six patients with unexplained chronic purulent sputum production, involvement of the respiratory tract, although relatively rare, has been increasingly recognized in patients with IBD [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The pulmonary complications of IBD, including those related to the medications used to treat IBD, are discussed here. An approach to the evaluation and diagnosis of interstitial pneumonia and discussions of the clinical manifestations of Crohn disease and ulcerative colitis are provided separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16435177">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of a variety of respiratory diseases is increased in patients with inflammatory bowel disease. Data from a large retrospective observational study indicated that, compared with a non-IBD cohort, patients with IBD had higher rates of the following disorders: bronchiectasis (46 percent increase), pulmonary vasculitis and interstitial pneumonia (52 percent increase), lung nodules (35 percent increase), pulmonary fibrosis (16 percent increase), and asthma (6 percent increase) [
         <a href="#rid2">
          2
         </a>
         ]. In comparing pulmonary comorbidities between patients with ulcerative colitis and Crohn disease, this study also found higher rates of bronchiectasis and pulmonary vasculitis and lower rates of chronic obstructive pulmonary disease in patients with ulcerative colitis compared with Crohn disease.
        </p>
        <p>
         Case series vary in terms of the proportions of patients with ulcerative colitis and Crohn disease who have associated lung disease [
         <a href="#rid3">
          3-6
         </a>
         ]. An important factor is whether disease is defined by clinical, radiographic, or pulmonary function criteria. In a series of 52 patients with IBD, abnormal pulmonary function tests were more common in patients with Crohn disease than ulcerative colitis (25 versus 6 percent), but abnormal computed tomography (CT) was seen in approximately 50 percent of patients with ulcerative colitis or Crohn disease [
         <a href="#rid4">
          4
         </a>
         ]. Another study of 601 patients with IBD (350 with ulcerative colitis, 251 with Crohn disease) found abnormal findings on high-resolution computed tomography (HRCT) scan in 48 percent with ulcerative colitis and 37 percent with Crohn disease, though only 10 percent of patients with an abnormal CT scan presented with respiratory symptoms [
         <a href="#rid7">
          7
         </a>
         ]. In a series of 563 patients with ulcerative colitis reported from Japan, 28 (5 percent) developed ulcerative colitis-related lung disease (including both symptoms and imaging findings) over a period of 77 months [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H112987388">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of pulmonary parenchymal and pleural disease associated with IBD is unknown. However, the more common airway inflammatory changes are thought to represent the same type of inflammatory changes that occur in the bowel [
         <a href="#rid8">
          8
         </a>
         ]. Although the underlying etiology of both IBD and associated pulmonary complications is unknown, research interest has focused on the interplay between the mucosal immune system and the microbial environment [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4077.html" rel="external">
          "Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5621233">
         <span class="h1">
          PRIMARY RESPIRATORY INVOLVEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary complications of IBD include inflammation of small and large airways, pulmonary parenchymal disease, serositis, and pulmonary embolism [
         <a href="#rid9">
          9-14
         </a>
         ]. These abnormalities are generally related to the underlying bowel disease, although interstitial lung disease can also be induced by administration of certain drugs, such as
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , 5-aminosalicylic acid,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , anti-TNF agents, and
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         [
         <a href="#rid15">
          15-19
         </a>
         ]. Patients with IBD may present with cough, dyspnea, chest pain, or an abnormal chest radiograph obtained for another reason. Often the initial history (including current medications) and physical examination will focus attention on a given type of lung involvement (eg, airway versus parenchymal).
        </p>
        <p>
         The three main patterns of presentation (airway disease, parenchymal disease, and pleural disease with serositis) have somewhat different characteristics in terms of sex preponderance and activity of the bowel disease [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A female preponderance of almost 2:1 is reported for bronchopulmonary complications as a whole and approximately 3:1 for bronchial complications.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bronchopulmonary complications follow the onset of inflammatory bowel disease in 80 to 85 percent of patients, precede bowel disease in 10 to 15 percent, and develop concomitantly in 5 to 10 percent. Almost one-half the patients with airway disease have undergone colectomy; in some cases, development of airway symptoms follows colectomy by days to weeks.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The majority of patients with serositis have active inflammatory bowel disease, while parenchymal lung disease often develops in the setting of inactive bowel disease. Serositis occurs with roughly equal frequency in each sex.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H112987945">
         <span class="h2">
          Airway involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory bowel disease is associated with inflammation of the trachea, bronchi, and bronchioles [
         <a href="#rid3">
          3,8,20-22
         </a>
         ]. In a review of 131 cases of respiratory involvement in IBD, approximately 41 percent presented with some form of airway inflammation  (
         <a class="graphic graphic_table graphicRef54855" href="/z/d/graphic/54855.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. The types of airway involvement in IBD include bronchiectasis, which is clinically the most common, acute and chronic tracheobronchitis, bronchiolitis, subglottic stenosis, and fistula formation [
         <a href="#rid3">
          3,19
         </a>
         ]. However, the most common abnormalities on high-resolution CT scan are centrilobular nodules and bronchial wall thickening [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchitis or bronchiectasis
         </strong>
         – Patients with IBD-associated bronchitis or bronchiectasis typically present with cough and variable amounts of mucopurulent sputum production [
         <a href="#rid23">
          23
         </a>
         ]. Cultures of bronchial secretions are unrevealing, and the symptoms are unresponsive to antibiotics. Chest radiographs are frequently normal or show nonspecific changes resulting from bronchial wall thickening or bronchiectasis. High-resolution chest computed tomography (HRCT) scanning is more sensitive than conventional chest radiographs, often demonstrating findings of bronchial wall thickening, dilated airways with thickened walls, or branched opacities suggestive of mucoid impaction [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On pulmonary function testing, an obstructive impairment with a reduced or normal forced vital capacity (FVC), a low forced expiratory volume (FEV
         <sub>
          1
         </sub>
         ), and a low FEV
         <sub>
          1
         </sub>
         /FVC is the most frequent finding. In contrast to asthma, however, airflow obstruction does not show significant reversibility following inhaled bronchodilator, and bronchoprovocation challenge (eg, histamine,
         <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">
          methacholine
         </a>
         ) does not reveal airway hyperresponsiveness. (See
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiolitis
         </strong>
         – Small airway involvement (bronchiolitis) can cause cough, variable sputum production, wheezing, and airflow obstruction. Pathologic findings include nonspecific inflammation, narrowing, and fibrosis of the small airways; granulomatous bronchiolitis has also been reported [
         <a href="#rid17">
          17,26
         </a>
         ]. Small airway involvement with IBD is associated with abnormalities in pulmonary function (eg, airflow obstruction and reduced diffusing capacity). The clinical manifestations of bronchiolitis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subglottic stenosis
         </strong>
         – Subglottic stenosis is associated with inflammation, friability, and inflammatory pseudotumors in the trachea [
         <a href="#rid27">
          27-29
         </a>
         ]. The primary symptoms are cough and dysphonia, although some patients develop upper airway obstruction with resulting stridor and severe dyspnea [
         <a href="#rid30">
          30
         </a>
         ]. A flow-volume loop may show variable extrathoracic obstruction. (See
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1465.html" rel="external">
          "Flow-volume loops", section on 'Variable extrathoracic obstruction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enteric-pulmonary fistulas
         </strong>
         – Enteric-pulmonary fistulas, such as colo-bronchial, ileo-bronchial, and esophago-bronchial, have been described in patients with Crohn disease [
         <a href="#rid17">
          17,31
         </a>
         ]. In a series of over 400 patients with IBD, five patients with colobronchial fistulae were reported [
         <a href="#rid17">
          17
         </a>
         ]. Four had left lower lobe pneumonia; clinical findings included fever, radiographic opacities, pleural effusion, and growth of enteric pathogens on culture. Esophageal Crohn disease is rare, but four cases of esophago-bronchial fistulae have been reported. These patients complained of dysphagia and had clinical evidence of pneumonia [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3552789461">
         <span class="h2">
          Asymptomatic abnormalities in pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have identified abnormalities in pulmonary function tests among patients with IBD [
         <a href="#rid4">
          4,18,32,33
         </a>
         ]. In a series of 82 patients with IBD and normal plain chest radiographs, 47 (57 percent) had abnormal findings on pulmonary function tests [
         <a href="#rid18">
          18
         </a>
         ]. Most of these patients had findings consistent with restrictive lung disease and a reduced diffusing capacity. A separate series of 85 patients with ulcerative colitis and 47 patients with Crohn disease found that diffusing capacity was significantly lower during exacerbations of bowel disease than when gastrointestinal disease was quiescent [
         <a href="#rid32">
          32
         </a>
         ]. No pulmonary symptoms were associated with these transient physiologic derangements. These results have been confirmed in other reports, suggesting that mild pulmonary inflammation commonly accompanies inflammation of the bowel [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Pulmonary parenchymal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with respiratory involvement with IBD, approximately 27 percent have parenchymal lung disease  (
         <a class="graphic graphic_table graphicRef54855" href="/z/d/graphic/54855.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Several patterns of parenchymal lung involvement have been described in IBD, with organizing pneumonia and interstitial lung disease (not otherwise specified) being most common [
         <a href="#rid3">
          3,15,19,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
         Lung infections should be considered in the differential diagnosis of pulmonary parenchymal disease in patients with IBD, particularly when patients present with fever, dyspnea, cough, and radiographic opacities. Information about community-acquired pneumonia and pneumonia in immunocompromised hosts is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">
          "Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">
          "Epidemiology of pulmonary infections in immunocompromised patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H112987822">
         <span class="h3">
          Organizing pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Organizing pneumonia (OP) presents in an acute or subacute fashion with variable combinations of fever, dyspnea, cough, and pleuritic chest pain [
         <a href="#rid3">
          3,35-37
         </a>
         ]. OP can also be a manifestation of drug-induced lung toxicity. (See
         <a class="local">
          'Drug-induced complications'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Chest radiographic findings range from patchy focal consolidation to diffuse opacities; HRCT scanning often demonstrates peripheral ground-glass opacities or areas of consolidation that may have an air bronchogram. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Chest imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H112987829">
         <span class="h3">
          Interstitial lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interstitial lung disease (ILD) in IBD is thought to reflect a spectrum of diseases, such as organizing pneumonia, nonspecific interstitial pneumonia, desquamative interstitial pneumonia (typically in smokers), eosinophilic pneumonia, and usual interstitial pneumonia [
         <a href="#rid19">
          19
         </a>
         ]. When mild or not progressive, it is often not evaluated histopathologically, so the exact type of ILD is not always identified. Drug-induced pulmonary toxicity is an important cause of ILD among patients with IBD. (See
         <a class="local">
          'Drug-induced complications'
         </a>
         below.)
        </p>
        <p>
         The clinical presentation of ILD is generally characterized by a subacute onset of dyspnea, crackles on chest examination, and radiographic findings of diffuse ground glass or reticular opacities, most prominent at the lung bases. Patients may have a stable course or manifest progressive respiratory insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         .)
        </p>
        <p>
         The bronchoalveolar lavage (BAL) fluid in IBD-associated ILD is usually lymphocytic. An elevated CD4:CD8 ratio in the BAL, a finding often described in sarcoidosis, has also been documented in patients with Crohn disease [
         <a href="#rid19">
          19,38,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H112987836">
         <span class="h3">
          Sarcoidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several cases of sarcoidosis coexisting with ulcerative colitis or Crohn disease have been reported [
         <a href="#rid17">
          17,38,40
         </a>
         ]. No clear etiologic association has been identified between inflammatory bowel disease and sarcoidosis. However, it has been suggested that there may be a pathogenetic relationship between sarcoidosis and Crohn disease, since bronchoalveolar lavage fluid lymphocytosis (with elevated CD4/CD8 ratios) and noncaseating granulomas in lung tissue can be seen in both disorders [
         <a href="#rid38">
          38,39
         </a>
         ]. In addition, four reports of the coexistence of Crohn disease and sarcoidosis in siblings suggest a potential genetic overlap [
         <a href="#rid17">
          17
         </a>
         ]. The clinical and radiographic manifestations of sarcoidosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H112987843">
         <span class="h3">
          Pulmonary infiltrates with eosinophilia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pulmonary infiltrates with eosinophilia (PIE) syndrome is a recognized complication of
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , which is commonly used in the therapy of ulcerative colitis. There are also case reports of eosinophilic pneumonia in patients taking
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         for IBD [
         <a href="#rid16">
          16,41-43
         </a>
         ]. However, the PIE syndrome can occur in patients with inflammatory bowel disease who have no history of using these medications [
         <a href="#rid11">
          11
         </a>
         ]. Eosinophilia is frequently present in the peripheral blood, and chest radiographs often show patchy peripheral opacities typical of chronic eosinophilic pneumonia. BAL eosinophilia is frequently present. (See
         <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">
          "Overview of pulmonary eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease", section on 'Eosinophilic BAL'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H112987850">
         <span class="h3">
          Necrobiotic nodules
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, necrobiotic lung nodules are described in patients with IBD [
         <a href="#rid44">
          44-48
         </a>
         ]. The nodules have a radiographic resemblance to the cavitating nodules seen with septic pulmonary emboli or granulomatosis with polyangiitis  (
         <a class="graphic graphic_diagnosticimage graphicRef70948" href="/z/d/graphic/70948.html" rel="external">
          image 1
         </a>
         ). Histologically, the nodules are composed of sterile aggregates of neutrophils with necrosis, findings that are similar to those of pyoderma gangrenosum, a cutaneous complication of inflammatory bowel disease  (
         <a class="graphic graphic_picture graphicRef60375" href="/z/d/graphic/60375.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid45">
          45
         </a>
         ]. In isolated case reports, the clinical presentation has included fever, cough, weight loss, and a flare of intestinal Crohn disease; in one patient concomitant cutaneous pyoderma gangrenosum was noted [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
         A separate case report described development of pulmonary necrobiotic nodules, associated with dyspnea, fever, pleuritic chest pain, and pleural effusion, four months after initiation of
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         , a monoclonal antibody to alpha-4 beta-7 integrin [
         <a href="#rid47">
          47
         </a>
         ]. Discontinuation of vedolizumab and initiation of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         led to resolution of the pleuropulmonary findings. (See
         <a class="medical medical_review" href="/z/d/html/4064.html" rel="external">
          "Dermatologic and ocular manifestations of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Pleural disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a rare complication of inflammatory bowel disease, serositis involving intrathoracic structures has occurred in the form of pleural effusions, pericarditis, pleuropericarditis, and myopericarditis  (
         <a class="graphic graphic_table graphicRef54855" href="/z/d/graphic/54855.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3,17,49
         </a>
         ]. Patients typically present with chest pain. The serosal fluid is exudative, with a cellular content generally composed primarily of neutrophils.
        </p>
        <p>
         Drugs are another potential cause of serositis [
         <a href="#rid50">
          50
         </a>
         ].
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          Sulfasalazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , commonly used medications for IBD, have been associated with pleural effusions, although not particularly in patients with IBD. A lupus-like syndrome sometimes with serositis has been reported in 10 patients receiving
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         for Crohn disease [
         <a href="#rid51">
          51
         </a>
         ]. All of the patients had a positive antinuclear antibody, some had a positive anti-double stranded DNA antibody, and three had a positive antihistone antibody, although it was not clear whether antihistone antibody testing was done in other patients. Symptoms and autoantibodies improved with discontinuation of the medication. (See
         <a class="local">
          'Drug-induced complications'
         </a>
         below.)
        </p>
        <p>
         A very rare but reported complication of Crohn disease is a colopleural fistula, which can lead to development of a fecopneumothorax [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Pulmonary embolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IBD are at increased risk for venous thromboembolism (VTE) [
         <a href="#rid19">
          19,53-64
         </a>
         ]. In a meta-analysis of 11 case-control and cohort studies, which included hospitalized and nonhospitalized patients, the relative risk for VTE among patients with IBD was estimated to be 2.20 (95% CI 1.83-2.65) [
         <a href="#rid65">
          65
         </a>
         ]. The risk of VTE appears to be further increased during IBD flares, as suggested by a cohort study in which the hazard ratio for VTE during disease flares was 8.4 (95% CI 5.5-12.8) [
         <a href="#rid61">
          61
         </a>
         ]. It is thought that patients with IBD have several risk factors for hypercoagulability, although no particular laboratory test has sufficient predictive value to identify patients at increased risk  (
         <a class="graphic graphic_table graphicRef68675" href="/z/d/graphic/68675.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Extraintestinal manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Extraintestinal manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DRUG-INDUCED COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A broad spectrum of pulmonary disease has been described associated with drugs used to treat IBD. The drugs implicated include
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , 5-aminosalicylic acid (5-ASA),
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         , anti-tumor necrosis factor (TNF) agents,
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         [
         <a href="#rid16">
          16,41,66
         </a>
         ].
        </p>
        <p>
         The Groupes d'Etudes de la Pathologie Pulmonaire Iatrogène maintains a frequently updated website listing drugs that have been associated with pneumonitis and a list of references (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pneumotox.com%2Fdrug%2Findex%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAebUs0tWBJH2E4P6NjJKXt7lfaz85Ary5D81ipOGXzyNa&amp;TOPIC_ID=4344" target="_blank">
          www.pneumotox.com
         </a>
         ) [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Sulfasalazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumonitis, commonly in conjunction with fever and rash, is a recognized complication of
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         therapy. Nearly half of affected patients present with the clinical syndrome of pulmonary infiltrates with eosinophilia [
         <a href="#rid16">
          16
         </a>
         ]. Cough and crackles on lung examination were commonly reported. Eosinophil counts in the peripheral blood ranged from 432 to 7500/mm
         <sup>
          3
         </sup>
         . (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         Other pulmonary disorders associated with
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         include nonspecific interstitial pneumonia, organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), granulomatous lung disease, and rarely pleural effusion [
         <a href="#rid3">
          3,68
         </a>
         ]. A pulmonary picture consistent with granulomatosis with polyangiitis has also been attributed to sulfasalazine [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          5-aminosalicylic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary toxicity attributable to 5-aminosalicylic acid (5-ASA or
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         ) is less common than with
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         . Affected patients may have diffuse or patchy basilar opacities on high-resolution computed tomography (HRCT) [
         <a href="#rid66">
          66,70
         </a>
         ]. Histopathologic patterns of inflammation include pulmonary eosinophilia [
         <a href="#rid41">
          41
         </a>
         ], organizing pneumonia, and bronchiolitis obliterans [
         <a href="#rid43">
          43,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung toxicity from
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         may have an acute, subacute, or chronic presentation; typical symptoms include nonproductive cough, dyspnea, fever, and malaise [
         <a href="#rid43">
          43,71
         </a>
         ]. Chest HRCT patterns associated with methotrexate toxicity include patchy ground glass or consolidative opacities, diffuse ground glass with or without reticulation, micronodules, and bilateral basilar reticular opacities. In one patient, lymphocytic bronchoalveolar lavage fluid was noted [
         <a href="#rid72">
          72
         </a>
         ]. Histopathologic findings include organizing pneumonia, diffuse alveolar damage, pulmonary fibrosis, granulomatous inflammation, eosinophilic pneumonitis, and nonspecific interstitial pneumonia. Methotrexate-induced pulmonary injury is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         has also been associated with drug-induced pleural effusion. (See
         <a class="local">
          'Pleural disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Azathioprine and 6-mercaptopurine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunomodulatory drugs, such as
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA) and
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         (6-MP), can potentiate the therapeutic effect of glucocorticoids and exert a glucocorticoid-sparing effect in patients with glucocorticoid-dependent ulcerative colitis. Drug-induced hypersensitivity pneumonitis is a rare but potentially serious complication of therapy with these agents, although it is more commonly reported in patients taking AZA for kidney transplant immunosuppression than for IBD [
         <a href="#rid31">
          31,73,74
         </a>
         ]. Clinical manifestations include dyspnea, cough, and fever [
         <a href="#rid73">
          73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         Other pathologic patterns, such as usual interstitial pneumonia and organizing pneumonia (formerly known as bronchiolitis obliterans with organizing pneumonia), have rarely been reported in patients with inflammatory bowel disease treated with AZA or 6-MP [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Anti-TNF agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         and
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , used to treat patients with Crohn disease and ulcerative colitis, and certolizumab, used in patients with Crohn disease, have been reported to cause interstitial pneumonitis in patients with rheumatoid arthritis and IBD, in addition to causing infectious complications, most notably tuberculosis [
         <a href="#rid75">
          75-81
         </a>
         ]. In some patients the pattern was consistent with drug-induced lupus and in others with usual interstitial pneumonia, nonspecific interstitial pneumonia, or organizing pneumonia [
         <a href="#rid77">
          77,78
         </a>
         ]. The risk of infliximab-associated pneumonitis appears greater among patients of older age or with a history of preexisting lung disease, although these risk factors are not always present [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">
          "Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Pulmonary disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus", section on 'Drug-induced lupus'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         has also been associated with development of serositis. (See
         <a class="local">
          'Pleural disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1802191052">
         <span class="h2">
          Ustekinumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          Ustekinumab
         </a>
         is an interleukin (IL)-12/23 antagonist used to treat Crohn disease and ulcerative colitis. Noninfectious pneumonitis has been reported with the use of this agent [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H425080393">
         <span class="h2">
          Janus kinase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Janus kinase (JAK) inhibitors,
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">
          upadacitinib
         </a>
         , have been used in the management of moderate to severe IBD. Tofacitinib is approved for use in ulcerative colitis, while upadacitinib is approved for use in Crohn disease and in ulcerative colitis. Reports have suggested an increased risk of thromboembolic events including pulmonary emboli in patients taking these JAK inhibitors [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16433751">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2986351039">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation and diagnosis of pulmonary complications of inflammatory bowel disease usually starts with an assessment of the severity of dyspnea, rapidity of onset of symptoms, and presence of medications that are known to cause lung toxicity or immunosuppression. For patients with a rapid onset of dyspnea, fever, or respiratory distress, pulmonary embolism, pneumonia, and drug toxicity should be evaluated promptly.
        </p>
        <p>
         For patients with a more indolent onset of disease, the workup usually starts with a complete blood count and differential, antinuclear antibodies and antihistone antibodies if drug-induced lung disease is suspected, pulmonary function testing (PFT), and a conventional chest radiograph. Further studies depend on the results of the initial studies and the suspected site of involvement. The following are some examples:
        </p>
        <p class="headingAnchor" id="H5620986">
         <span class="h2">
          Airway involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of airway involvement with inflammatory bowel disease is suspected based on the clinical presentation of cough and sputum production in a patient without evidence of an infectious tracheobronchitis or asthma. In patients with chronic bronchitis, bronchiectasis, or bronchiolitis, pulmonary function tests usually reveal airflow obstruction, but in contrast to asthma do not show significant reversibility following inhaled bronchodilator or
         <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">
          methacholine
         </a>
         hyperresponsiveness. Direct visualization via flexible bronchoscopy is generally not necessary unless airway compromise is suspected or the patient has hemoptysis. Irregular and erythematous mucosa, exuberant inflammatory tissue, ulcerations, and narrowing of the airways have been described [
         <a href="#rid3">
          3,20
         </a>
         ]. (See
         <a class="local">
          'Airway involvement'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/543.html" rel="external">
          "Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Pulmonary function testing'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiectasis
         </strong>
         – The diagnosis of bronchiectasis is usually based on the presence of typical chest high-resolution computed tomography (HRCT) findings of airway dilation (ie, 1.5 times the diameter of the adjacent vessel or wider), often accompanied by bronchial wall thickening. (See
         <a class="local">
          'Airway involvement'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults", section on 'Computed tomography'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiolitis
         </strong>
         – The diagnosis of bronchiolitis is suggested when airflow limitation is irreversible and associated with a gas transfer abnormality in a nonsmoker. The most consistent abnormalities on HRCT are expiratory air trapping (mosaic or diffuse) and bronchiolar wall thickening (eg, centrilobular nodules and “tree-in-bud” opacities). In addition, a pattern of diffuse ground glass opacity with a mosaic pattern of attenuation is seen in some patients. A firm diagnosis of bronchiolitis requires an open or thoracoscopic lung biopsy. (See
         <a class="local">
          'Airway involvement'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tracheal disease
         </strong>
         – Tracheal involvement, suggested by the combination of dyspnea on exertion and a clear conventional chest radiograph (with or without stridor), is evaluated with a flow-volume loop; flattening of the inspiratory loop suggests extrathoracic variable obstruction  (
         <a class="graphic graphic_figure graphicRef76811" href="/z/d/graphic/76811.html" rel="external">
          figure 1
         </a>
         ). The expiratory loop may be normal. CT of the trachea with three-dimensional reconstruction can provide additional support with visualization of the degree and extent of airway narrowing. The diagnosis is confirmed by direct visualization. (See
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1465.html" rel="external">
          "Flow-volume loops", section on 'Variable intrathoracic obstruction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5620994">
         <span class="h2">
          Interstitial lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with interstitial lung disease associated with IBD, several processes must be differentiated: fibrotic interstitial lung disease, sarcoidosis, drug-induced disease, superimposed infection, and concomitant connective tissue disease-associated interstitial lung disease. After a careful review of the history of medication use and potential exposures to infectious agents, the evaluation typically involves laboratory testing to assess for peripheral blood eosinophilia and antinuclear antibody positivity, pulmonary function testing to assess the severity of restrictive impairment, and HRCT of the lungs to determine the pattern and distribution of opacities. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
         The combination of diffuse pulmonary opacities and peripheral eosinophilia creates a high suspicion for drug-induced lung disease, although eosinophilic pneumonias are seen in patients with IBD without a drug association. Fungal pneumonia and tropical filarial infection can also cause eosinophilia, particularly in endemic areas. (See
         <a class="local">
          'Drug-induced complications'
         </a>
         above and
         <a class="local">
          'Interstitial lung disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">
          "Overview of pulmonary eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">
          "Tropical pulmonary eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">
          "Nonresolving pneumonia", section on 'Fungi'
         </a>
         .)
        </p>
        <p>
         In the absence of eosinophilia, the diagnosis of drug-induced lung toxicity is based on the clinical presentation (eg, clinical syndrome of drug-induced lupus versus atypical pneumonia), the likelihood of the drug in question causing lung toxicity, exclusion of other etiologies, and a trial of drug discontinuation (dechallenge). (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">
          "Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on 'Side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Flexible bronchoscopy with bronchoalveolar lavage (BAL) is typically performed to obtain samples for cell counts, microbiologic stains and cultures, and cytology. The BAL findings are more helpful in excluding processes such as infection or malignancy than in confirming a specific type of interstitial lung disease, although an eosinophilic BAL in a patient with IBD is more likely to be drug-induced. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         For patients with significant respiratory impairment or evidence of progressive deterioration in lung function, further evaluation typically includes lung biopsy via thoracoscopy or thoracotomy. The main role for lung biopsy is to characterize the histopathologic pattern and to exclude other processes, such as tumor or infection. Organizing pneumonia on histopathology can be drug-induced or associated with the underlying IBD. (See
         <a class="local">
          'Organizing pneumonia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5621002">
         <span class="h2">
          Pleuritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pleuritic type chest pain or radiographic evidence of pleural or other serosal involvement, it is important to exclude infection, particularly in patients taking immunosuppressive agents. Laboratory testing (eg, antinuclear antibodies, antihistone antibodies, antidouble-stranded DNA antibodies) may be indicated to look for drug-induced lupus or a concomitant connective tissue disease. A diagnostic thoracentesis is typically performed to exclude infection or malignancy if an adequate amount of free-flowing pleural fluid is present. (See
         <a class="medical medical_review" href="/z/d/html/6686.html" rel="external">
          "Ultrasound-guided thoracentesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">
          "Pleural fluid analysis in adults with a pleural effusion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5621010">
         <span class="h2">
          Pulmonary embolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation for suspected thromboembolic disease typically includes computed tomography pulmonary angiography (CTPA) and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
         Patients with an insidious onset of dyspnea, hypoxemia on exertion, a reduced diffusing capacity, and relative lung parenchymal sparing may have chronic thromboembolic pulmonary hypertension. Transthoracic echocardiography shows elevated pulmonary artery pressures, which can be confirmed with right heart catheterization. (See
         <a class="local">
          'Pulmonary embolism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of the various pulmonary complications of IBD depends on the site, severity, and type of involvement [
         <a href="#rid9">
          9
         </a>
         ]. The activity of the underlying IBD does not always correlate with the activity of lung involvement, so lung involvement is often treated independently. If the IBD is flaring at the same time as the lung involvement, therapy is tailored to achieve a combination that will address both processes. If the patient has a drug-induced pulmonary toxicity, the treatment of the IBD will need to be changed to an alternate agent. (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis"
         </a>
         .)
        </p>
        <p>
         Smoking cessation should be strongly encouraged for those who smoke [
         <a href="#rid85">
          85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">
          "Pharmacotherapy for smoking cessation in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8794801">
         <span class="h2">
          Airway involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Airway compromise due to subglottic stenosis requires urgent attention to secure the airway via endotracheal intubation and/or rigid bronchoscopy. Additional airway interventions such as dilation, laser therapy, or stenting depend on the assessment of the airway at the time of bronchoscopy. (See
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"
         </a>
         .)
        </p>
        <p>
         Patients with potentially life-threatening airway inflammation, such as subglottic stenosis, are typically treated with systemic glucocorticoids, based on clinical experience rather than clinical trial data [
         <a href="#rid3">
          3
         </a>
         ]. We usually start with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg lean body weight per day to a maximum of 60 mg per day, given as a single oral dose in the morning. For patients who are unable to take oral medication, an intravenous preparation is substituted, such as
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         60 to 80 mg in divided doses. As the airway inflammation improves, intravenous glucocorticoids are changed to oral and then inhaled preparations.
        </p>
        <p>
         For patients who have IBD-associated airway involvement without immediate airway compromise, inhaled glucocorticoid therapy is frequently effective, although formal data are limited [
         <a href="#rid3">
          3
         </a>
         ]. In a case series, among 12 patients treated with inhaled glucocorticoids, nine had a significant improvement, but three experienced progressive and disabling disease [
         <a href="#rid3">
          3
         </a>
         ]. Relatively high doses (eg,
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         1500 to 2000 mcg/day) were needed in some patients. We typically start with the equivalent of
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         500 mcg twice daily and adjust based on the response to therapy. Inflammation in the larger airways tends to be more responsive than bronchiolitis, possibly due to relatively poor delivery of the inhaled medication to the affected small airways. Patients with copious sputum production (greater than 50 mL/day) and those with bronchiectasis are less likely to respond to inhaled glucocorticoids. Antibiotics are indicated in the setting of an acute infectious exacerbation of bronchiectasis (see
         <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">
          "Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"
         </a>
         ). After excluding an infectious cause for copious sputum production, we consider adding
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.5 to 1 mg/kg lean body weight per day to a maximum of 60 mg per day, given as a single oral dose in the morning.(See
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Enteric-bronchial fistulae typically require systemic antibiotics to treat associated pulmonary parenchymal infection and then surgical resection to prevent recurrence. The treatment of fistulae due to Crohn disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults", section on 'Fistulizing disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">
          "Surgical management of Crohn disease", section on 'Fistula'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8794843">
         <span class="h2">
          Pulmonary parenchymal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic patients with pulmonary parenchymal complications of IBD generally require oral glucocorticoid therapy, once infection and drug-induced disease have been excluded. Management is typically based on the underlying histopathology. Thus, treatment of organizing pneumonia, eosinophilic pneumonia, nonspecific interstitial pneumonia, or sarcoidosis would follow treatment recommendations for these diseases, most of which are treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at an initial dose of 0.5 to 1.0 mg/kg per day, up to a daily dose of 60 mg. The higher initial doses are usually chosen for patients with more severe lung involvement and for noneosinophilic conditions; lower doses are usually adequate for eosinophilic lung diseases and sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">
          "Idiopathic acute eosinophilic pneumonia", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4306.html" rel="external">
          "Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Overview of treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         The optimal duration of systemic glucocorticoid treatment has not been established, but generally is based on the response to therapy and the timing of tapering established for the underlying histopathology. In general, for patients who respond or stabilize with treatment, the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose is gradually tapered, aiming to reach 5 to 10 mg daily or on alternate days, by the end of 6 months, with attempted cessation after one year of therapy.
        </p>
        <p>
         Most patients with parenchymal lung disease due to IBD have a good response to glucocorticoid therapy [
         <a href="#rid3">
          3
         </a>
         ]. However, for those with progressive pulmonary dysfunction despite therapy with systemic glucocorticoids, immunomodulatory therapy is usually added. For patients with ongoing need for immunomodulatory therapy to control their IBD, the optimal agent to control their IBD is usually chosen. However, if the patient’s IBD is not active, the choice of a second-line agent is based on the specific underlying lung histopathology. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H94183192">
         <span class="h2">
          Serositis
         </span>
         <span class="headingEndMark">
          —
         </span>
         After exclusion of infectious processes, patients who have symptoms caused by pleuritis, pericarditis, or myopericarditis due to IBD are typically treated with a nonsteroidal antiinflammatory drug (NSAID), such as
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         400 to 800 mg three times daily, unless the IBD is active and the patient is at risk for gastrointestinal bleeding. NSAIDs have been used successfully in other forms of inflammatory serositis, although the experience in patients with IBD is limited. Systemic glucocorticoid therapy is an alternative if the patient does not respond to NSAIDs or is unable to take them. Based on experience with recurrent pericarditis, we typically initiate therapy with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (0.2 to 0.5mg/kg/day; ie, 25mg for the average patient) for four weeks and then taper as tolerated. As NSAID therapy can precipitate a flare of IBD, careful patient education and close follow up is needed during NSAID therapy. (See
         <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">
          "Recurrent pericarditis", section on 'Glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">
          "Definitions, epidemiology, and risk factors for inflammatory bowel disease", section on 'NSAIDs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8794815">
         <span class="h2">
          Pulmonary thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with IBD, the choice of treatment of acute pulmonary thromboembolism depends on the expected risk of gastrointestinal bleeding. For patients with active IBD, especially with significant bleeding, an inferior vena cava filter is usually inserted and anticoagulation deferred until the bleeding is under control. If the patient is not deemed to be at increased risk for gastrointestinal bleeding, the usual guidelines for anticoagulation are followed. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H112987881">
         <span class="h2">
          Drug-induced lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients taking a medication for IBD that has been associated with pulmonary toxicity who present with fever, cough, and radiographic opacities, appropriate antimicrobial therapy is usually initiated. In addition, the implicated drug is empirically discontinued while awaiting culture results and a response to drug discontinuation [
         <a href="#rid3">
          3,16,17
         </a>
         ]. Drug-induced lung inflammation and peripheral blood eosinophilia, if present, usually resolve with drug discontinuation [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         For patients with severe respiratory insufficiency due to drug-induced pulmonary disease or lack of improvement with drug discontinuation, we initiate therapy with systemic glucocorticoids. This choice is based on clinical experience, as clinical data in support of this therapy are lacking. The initial dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is usually 1 mg/kg per day in a single morning dose. For patients who have had an episode of drug-induced pulmonary toxicity, we avoid reintroduction of that agent.
        </p>
        <p>
         When it is unclear whether a particular drug contributed to the lung injury, decisions concerning cessation of drug therapy should consider the availability of alternative agents and the relative severity of the pulmonary disease and the IBD, which could flare if the drug is withdrawn.
        </p>
        <p class="headingAnchor" id="H272016037">
         <span class="h1">
          PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with consensus guidelines from the Canadian Association of Gastroenterology, which recommend anticoagulant prophylaxis against venous thromboembolism (VTE) for patients over age 18 years who are hospitalized for a flare of IBD without severe bleeding, independent of the reason for hospitalization, except for planned admissions &lt;48 hours in duration for diagnostic testing or nonsurgical procedures [
         <a href="#rid64">
          64
         </a>
         ]. For patients hospitalized with an IBD flare and severe gastrointestinal bleeding, mechanical rather than anticoagulant thromboprophylaxis is recommended. The prevention of VTE in medical patients is described separately. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
         For adult outpatients with a moderate-to-severe flare of IBD, the same guidelines suggest not initiating anticoagulant VTE prophylaxis in those without a prior history of VTE, but suggest that anticoagulant VTE prophylaxis be administered to those patients with a previous episode of VTE, unless all episodes of VTE occurred after major surgery [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Surgical patients with IBD are considered to be at increased risk for VTE. Anticoagulant prophylaxis is recommended for patients with IBD undergoing major abdominal-pelvic or other general surgical procedures [
         <a href="#rid64">
          64
         </a>
         ]. For those patients who are actively bleeding or at increased risk for bleeding, mechanical methods of thromboprophylaxis are preferred. These choices are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16433788">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pleuropulmonary complications
         </strong>
         – Pleuropulmonary complications of inflammatory bowel disease (IBD), although uncommon, include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Airway inflammation
         </strong>
         – In patients with IBD, inflammation of the trachea, bronchi, and bronchioles may develop before or after bowel resection and rarely preceding the onset of IBD. Bronchiectasis is the most common form of airway involvement, but subglottic stenosis, airway-enteral fistulae, bronchitis, and bronchiolitis also occur. (See
         <a class="local">
          'Airway involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diffuse lung parenchymal disease
         </strong>
         – Several patterns of diffuse lung parenchymal involvement have been described in IBD, including organizing pneumonia, eosinophilic pneumonia, nonspecific interstitial lung disease, and sarcoidosis. (See
         <a class="local">
          'Pulmonary parenchymal disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pleuropericarditis
         </strong>
         – IBD-associated pleuropericarditis may present with pleural effusions, pericarditis, pleuropericarditis, and/or myopericarditis. The pleural fluid is exudative, with a cellular content composed primarily of neutrophils. Rarely, pleural-enteric fistulas occur. (See
         <a class="local">
          'Pleural disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug-induced lung disease
         </strong>
         – Most of the drugs used to treat IBD have been implicated in drug-induced pulmonary disease. Drug-induced lung diseases associated with these agents include pulmonary infiltrates with eosinophilia (PIE) syndrome, organizing pneumonia, a hypersensitivity syndrome (fever, cough, dyspnea, radiographic opacities), interstitial pneumonitis, reactivation of
         <em>
          Mycobacterium tuberculosis
         </em>
         , and development of other opportunistic infections. (See
         <a class="local">
          'Drug-induced complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – The evaluation and diagnosis of pulmonary complications of inflammatory bowel disease usually starts with an assessment of the severity of dyspnea, rapidity of onset of symptoms, and presence of medications that are known to cause lung toxicity or immunosuppression. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a more rapid onset of dyspnea, fever, or respiratory distress, pulmonary embolism, pneumonia, and subglottic stenosis should be evaluated promptly.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a more indolent onset of disease, the workup usually starts with a complete blood count and differential, antinuclear antibodies and antihistone antibodies if drug-induced lung disease is suspected, pulmonary function testing (PFT), and a conventional chest radiograph.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with airflow limitation on PFTs, the key next steps are determining the severity of airway compromise, whether subglottic stenosis may be present, and whether reversible airflow obstruction is more suggestive of asthma than IBD-associated airway inflammation. (See
         <a class="local">
          'Airway involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-resolution computed tomography is performed in patients suspected of having bronchiectasis, bronchiolitis, diffuse lung parenchymal disease, or drug-induced lung disease; computed tomography pulmonary angiography (CTPA) is used for suspected pulmonary embolism. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drug(s) suspected of causing lung toxicity should be withheld; improvement following drug discontinuation supports a drug-induced process. (See
         <a class="local">
          'Drug-induced complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The treatment of the various pulmonary complications of IBD depends on the site, severity, and type of involvement. The activity of the underlying IBD does not always correlate with the activity of lung involvement, so the lung involvement is often treated independently. If the IBD is flaring at the same time as the lung involvement, therapy is tailored to achieve a combination that will address both processes simultaneously. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Subglottic stenosis
         </strong>
         – Airway compromise due to subglottic stenosis requires urgent attention to secure the airway via endotracheal intubation and/or rigid bronchoscopy. Additional airway interventions such as dilation, laser therapy, or stenting depend on the assessment of the airway at the time of bronchoscopy. In addition, we suggest initiation of systemic glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The usual dose is
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg lean body weight per day to a maximum of 60 mg/day, given as a single oral dose in the morning. Systemic glucocorticoids are tapered and transitioned to inhaled glucocorticoids as the patient improves. (See
         <a class="local">
          'Airway involvement'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">
          "Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tracheobronchitis and bronchiolitis
         </strong>
         – For patients who have IBD-associated airway involvement without immediate airway compromise, we suggest initial administration of inhaled glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Relatively high doses of an inhaled glucocorticoid (eg,
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         1500 to 2000 mcg/day or
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         500 to 1000 mcg/day) may be needed. For patients who do not have an adequate response to inhaled glucocorticoid therapy, we suggest initiation of systemic glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We usually start with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.5 to 1 mg/kg lean body weight per day to a maximum of 60 mg/day, given as a single oral dose in the morning. (See
         <a class="local">
          'Airway involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary parenchymal disease
         </strong>
         – IBD-associated interstitial lung disease is generally treated according to the underlying histopathology. As an example, treatment of organizing pneumonia, eosinophilic pneumonia, nonspecific interstitial pneumonia, or sarcoidosis would follow treatment recommendations for these diseases as described separately. (See
         <a class="local">
          'Pulmonary parenchymal disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serositis
         </strong>
         – For patients with IBD-associated serositis whose IBD does not place them at increased risk for gastrointestinal bleeding, we suggest initial therapy with a nonsteroidal anti-inflammatory drug (NSAID) rather than observation or other options (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A reasonable choice is
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         600 mg three times daily or the equivalent. However, NSAID therapy may exacerbate underlying IBD, so ongoing monitoring is needed. Systemic glucocorticoid therapy is an alternative if the patient does not respond to NSAIDs. (See
         <a class="local">
          'Serositis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug-induced lung toxicity
         </strong>
         – For patients with IBD and suspected drug-induced lung toxicity (eg, due to
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , 5-aminosalicylic acid,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         , anti-TNF agents, or
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         ), the first step is to discontinue the culprit drug (dechallenge). (See
         <a class="local">
          'Drug-induced lung disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with drug-induced lung toxicity who present with severe respiratory insufficiency or have an incomplete response to drug discontinuation, we suggest initiation of oral glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The initial dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is usually 1 mg/kg per day up to 60 mg in a single morning dose. Rechallenge with a culprit drug is avoided, although data on the exact risk of recurrent lung disease are lacking. (See
         <a class="local">
          'Drug-induced lung disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H260506526">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed to earlier versions of this topic review and was a section editor for UpToDate in Gastroenterology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pemmasani G, Loftus EV, Tremaine WJ. Prevalence of Pulmonary Diseases in Association with Inflammatory Bowel Disease. Dig Dis Sci 2022; 67:5187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunc B, Filik L, Bilgic F, et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol Belg 2006; 69:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moda M, Suga M, Kasai S, et al. Incidence, Characteristics, Clinical Course, and Risk Factors of Ulcerative Colitis-related Lung Diseases. Chest 2022; 162:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato H, Okada F, Matsumoto S, et al. Chest High-resolution Computed Tomography Findings in 601 Patients with Inflammatory Bowel Diseases. Acad Radiol 2018; 25:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higenbottam T, Cochrane GM, Clark TJ, et al. Bronchial disease in ulcerative colitis. Thorax 1980; 35:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh S, Deshwal H, Haraf R, et al. Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies. CHEST Pulmonary 2023; 1:100018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sostegni R, Daperno M, Pera A. Pulmonary manifestations of inflammatory bowel disease. Dig Liver Dis 2007; 39:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J 2000; 15:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu DG, Ji XQ, Liu X, et al. Pulmonary manifestations of Crohn's disease. World J Gastroenterol 2014; 20:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kröner PT, Lee A, Farraye FA. Respiratory Tract Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021; 27:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003; 27:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzela L, Vavrecka A, Prikazska M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology 1999; 46:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuźniar T, Sleiman C, Brugière O, et al. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansi A, Cucchiara S, Greco L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med 2000; 161:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayraktaroglu S, Basoglu O, Ceylan N, et al. A rare extraintestinal manifestation of ulcerative colitis: tracheobronchitis associated with ulcerative colitis. J Crohns Colitis 2010; 4:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus P, Colby TV. Bronchiectasis in inflammatory bowel disease. Eur Respir Monogr 2011; 52:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg K, Lynch DA, Newell JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging 1993; 8:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandenplas O, Casel S, Delos M, et al. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkcaldy J, Lim WS, Jones A, Pointon K. Stridor in Crohn disease and the use of infliximab. Chest 2006; 130:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plataki M, Tzortzaki E, Lambiri I, et al. Severe airway stenosis associated with Crohn's disease: case report. BMC Pulm Med 2006; 6:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farkas ZC, Keshishyan S, Chakinala RC, et al. Tracheobronchitis with stridor in a patient with ulcerative colitis. Ann Transl Med 2018; 6:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen WJ, Bierig LN, Beuther DA, Miller YE. Stridor in a 47-year-old man with inflammatory bowel disease. Chest 2006; 129:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casella G, Villanacci V, Di Bella C, et al. Pulmonary diseases associated with inflammatory bowel diseases. J Crohns Colitis 2010; 4:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzanakis N, Bouros D, Samiou M, et al. Lung function in patients with inflammatory bowel disease. Respir Med 1998; 92:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marvisi M, Borrello PD, Brianti M, et al. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J 2000; 16:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cozzi D, Moroni C, Addeo G, et al. Radiological Patterns of Lung Involvement in Inflammatory Bowel Disease. Gastroenterol Res Pract 2018; 2018:5697846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinneen HS, Samiullah S, Lenza C. Cryptogenic organizing pneumonia: a rare extra-intestinal manifestation of Crohn's disease. J Crohns Colitis 2014; 8:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cebrián García A, Ruiz-Clavijo D, Irisarri Garde R, et al. Bronchiolitis obliterans organizing pneumonia in Crohn's disease. Gastroenterol Hepatol 2019; 42:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Chen Y, Zhao L. Organizing pneumonia: a rare pulmonary manifestation of well-controlled ulcerative colitis. J Thorac Dis 2018; 10:E634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smiéjan JM, Cosnes J, Chollet-Martin S, et al. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bewig B, Manske I, Böttcher H, et al. Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage. Respiration 1999; 66:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theodoropoulos G, Archimandritis A, Davaris P, et al. Ulcerative colitis and sarcoidosis: a curious association-report of a case. Dis Colon Rectum 1981; 24:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanigawa K, Sugiyama K, Matsuyama H, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999; 66:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saltzman K, Rossoff LJ, Gouda H, Tongia S. Mesalamine-induced unilateral eosinophilic pneumonia. AJR Am J Roentgenol 2001; 177:257.
          </a>
         </li>
         <li class="breakAll">
          Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwatrz MI, King TE, Jr (Eds), People's Publishing House, Shelton, CT 2011. p.637.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson BA, Kaplan JL, El Saleeby CM, et al. Case records of the Massachusetts General Hospital. Case 39-2014. A 9-year-old girl with Crohn’s disease and pulmonary nodules. N Engl J Med 2014; 371:2418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasuga I, Yanagisawa N, Takeo C, et al. Multiple pulmonary nodules in association with pyoderma gangrenosum. Respir Med 1997; 91:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease. Can J Gastroenterol 2004; 18:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myc LA, Girton MR, Stoler MH, Davis EM. Necrobiotic Pulmonary Nodules of Crohn's Disease in a Patient Receiving Vedolizumab. Am J Respir Crit Care Med 2019; 199:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Kersh K, Fraig M, Cavallazzi R, et al. Pulmonary necrobiotic nodules in Crohn's disease: a rare extra-intestinal manifestation. Respir Care 2014; 59:e190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbaum AJ, Murphy PJ, Engel JJ. Pleurisy during the course of ulcerative colitis. J Clin Gastroenterol 1983; 5:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barisiae G, Krivokapiae Z, Adziae T, et al. Fecopneumothorax and colopleural fistula - uncommon complications of Crohn's disease. BMC Gastroenterol 2006; 6:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quera R, Shanahan F. Thromboembolism--an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004; 99:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonoda K, Ikeda S, Mizuta Y, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004; 39:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:2272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996; 91:1039.
          </a>
         </li>
         <li class="breakAll">
          Foucher P, Camus P. Pneumotox online: the drug-induced lung diseases. www.pneumotox.com (Accessed on April 07, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest 1992; 101:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salerno SM, Ormseth EJ, Roth BJ, et al. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996; 110:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain N, Petruff C, Bandyopadhyay T. Mesalamine lung toxicity. Conn Med 2010; 74:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis 2010; 4:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brechmann T, Heyer C, Schmiegel W. [Methotrexate-induced pneumonitis in a woman with Crohn's disease]. Dtsch Med Wochenschr 2007; 132:1759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weatherhead M, Masson S, Bourke SJ, et al. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis 2006; 12:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heraganahally SS, Au V, Kondru S, et al. Pulmonary toxicity associated with infliximab therapy for ulcerative colitis. Intern Med J 2009; 39:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casanova MJ, Chaparro M, Valenzuela C, et al. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. World J Gastroenterol 2015; 21:2260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glaspole IN, Hoy RF, Ryan PF. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2013; 52:2302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veerappan SG, O'Morain CA. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2009; 21:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinker A, Cheng C, Chan V. Association of Noninfectious Pneumonia With Ustekinumab Use. JAMA Dermatol 2019; 155:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandborn WJ, Panés J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 2019; 50:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017; 112:241.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4344 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1267553" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Unexplained bronchopulmonary disease with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35142913" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of Pulmonary Diseases in Association with Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8502168" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The lung in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17168120" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11866276" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35691329" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Incidence, Characteristics, Clinical Course, and Risk Factors of Ulcerative Colitis-related Lung Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29195785" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Chest High-resolution Computed Tomography Findings in 601 Patients with Inflammatory Bowel Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7444824" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bronchial disease in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10678619" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical and radiological characteristics of lung disease in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267308" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pulmonary manifestations of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10678613" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The lung in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24415866" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pulmonary manifestations of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32448912" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Respiratory Tract Manifestations of Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548168" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Noninfectious lung pathology in patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11999006" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sulphasalazine and lung toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12769444" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pulmonary manifestations of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10430329" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary complications in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296657" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Thoracic manifestations of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10678648" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Severe tracheobronchial stenosis in a patient with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10712362" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Bronchial hyperresponsiveness in children and adolescents with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21122581" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A rare extraintestinal manifestation of ulcerative colitis: tracheobronchitis associated with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Bronchiectasis in inflammatory bowel disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315712" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9631822" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Large airway disease associated with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9817724" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Granulomatous bronchiolitis associated with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899863" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Stridor in Crohn disease and the use of infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16603056" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Severe airway stenosis associated with Crohn's disease: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30596075" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tracheobronchitis with stridor in a patient with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16608963" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Stridor in a 47-year-old man with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21122533" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pulmonary diseases associated with inflammatory bowel diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9692115" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lung function in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11153600" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30158965" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Radiological Patterns of Lung Involvement in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24090908" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cryptogenic organizing pneumonia: a rare extra-intestinal manifestation of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578017" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bronchiolitis obliterans organizing pneumonia in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30233901" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Organizing pneumonia: a rare pulmonary manifestation of well-controlled ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3940500" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10516546" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7238242" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ulcerative colitis and sarcoidosis: a curious association-report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9973695" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mesalazine-induced eosinophilic pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11418451" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mesalamine-induced unilateral eosinophilic pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11418451" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mesalamine-induced unilateral eosinophilic pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25517709" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Case records of the Massachusetts General Hospital. Case 39-2014. A 9-year-old girl with Crohn’s disease and pulmonary nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9338053" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Multiple pulmonary nodules in association with pyoderma gangrenosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15565210" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30156859" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Necrobiotic Pulmonary Nodules of Crohn's Disease in a Patient Receiving Vedolizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25233391" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pulmonary necrobiotic nodules in Crohn's disease: a rare extra-intestinal manifestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6663044" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pleurisy during the course of ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696692" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19880688" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16756646" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Fecopneumothorax and colopleural fistula - uncommon complications of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14687149" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Venous thromboembolism in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15735803" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15447758" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Thromboembolism--an important manifestation of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15549447" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15016749" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17420352" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Predictors of outcome in chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21407182" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Venous thromboembolism in inflammatory bowel disease: an epidemiological review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20546736" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20149425" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18684186" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21339206" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24462530" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23550660" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8633548" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Mesalamine-induced lung toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8633548" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Mesalamine-induced lung toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1348220" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sulfasalazine-induced pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8697866" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20509416" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Mesalamine lung toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21122509" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Methotrexate-induced pneumonitis in a patient with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17713885" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : [Methotrexate-induced pneumonitis in a woman with Crohn's disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667053" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15362028" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11596589" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16670533" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Interstitial pneumonitis after infliximab therapy for Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21277618" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17632266" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19769687" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pulmonary toxicity associated with infliximab therapy for ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25717268" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23661426" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19398919" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30540343" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Association of Noninfectious Pneumonia With Ustekinumab Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31599001" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28071656" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
